Letermovir oral/injection and Venclexta Starting Pack
Determining the interaction of Letermovir oral/injection and Venclexta Starting Pack and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using venetoclax together with letermovir is generally not recommended. Combining these medications may significantly increase the blood levels and effects of venetoclax. This may increase your risk of developing tumor lysis syndrome, a serious condition that is caused by the rapid breakdown of cancer cells and that can lead to kidney failure and even death. In addition, you may be more likely to experience other side effects such as nausea; vomiting; diarrhea; fatigue; and impaired bone marrow function resulting in low numbers of different types of blood cells, which can increase the risk of anemia, bleeding problems, and infections. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of venetoclax, which is a substrate of the isoenzyme. In 11 previously treated non-Hodgkin's lymphoma patients, venetoclax peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2.3- and 6.4-fold, respectively, when coadministered with 400 mg once daily for 7 days of ketoconazole, a potent CYP450 3A4 inhibitor that also inhibits P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Increased venetoclax exposure may potentiate the risk of tumor lysis syndrome, particularly at initiation of therapy and during the dosage ramp-up phase, as well as other adverse effects such as diarrhea, nausea, vomiting, neutropenia, anemia, and thrombocytopenia.
MANAGEMENT: Concomitant use of venetoclax with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the CYP450 3A4 inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.
- "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: letermovir
Brand name: Prevymis
Synonyms: Letermovir (oral/injection), Letermovir
Generic Name: venetoclax
Brand name: Venclexta, Venclexta Starting Pack
Synonyms: Venclexta
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Letermovir oral/injection-Venetoclax
- Letermovir oral/injection-Venipuncture CPI
- Letermovir oral/injection-Venipuncture PX1
- Letermovir oral/injection-Venlafaxine
- Letermovir oral/injection-Venlafaxine ER
- Letermovir oral/injection-Venlafaxine ER Capsules
- Venclexta Starting Pack-Letermovir Tablets
- Venclexta Starting Pack-Letrozole
- Venclexta Starting Pack-Letrozole and ribociclib
- Venclexta Starting Pack-Leucovorin
- Venclexta Starting Pack-Leucovorin Calcium
- Venclexta Starting Pack-Leucovorin injection